GlassScriptPhysician profile
Mark J Alberts
NPI 1992795140
$211,768.03
in general payments reported to CMS, 2019-2025
21 companies · $6,010 in 2025
The $6,010 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $32K · 2021: $15K · 2022: $19K · 2023: $13K · 2024: $3,290 · 2025: $6,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $5,573 · Travel and Lodging: $3,962 · Food and Beverage: $2,582 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,327.00 |
| Consulting Fee | $5,572.50 |
| Travel and Lodging | $3,962.36 |
| Food and Beverage | $2,582.29 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $52,985.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52,100.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $34,571.51 | 2021-2025 | Andexxa |
| Janssen Scientific Affairs, LLC | $20,750.00 | 2019-2020 | |
| Boehringer Ingelheim (Phil.) INC. | $14,640.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14,337.95 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $13,616.92 | 2019-2021 | |
| Pfizer INC. | $3,934.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,887.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $983.13 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $269.11 | 2024-2025 | Kisunla, Amyvid |
| Eisai INC. | $137.06 | 2023-2025 | |
| Depuy Synthes Sales INC. | $136.21 | 2025 | Embotrap |
| Amgen INC. | $124.45 | 2019 | |
| Axsome Therapeutics, INC. | $112.78 | 2025 | Symbravo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.79 | 2023 | Austedo Xr |
| Medtronic Vascular, INC. | $38.42 | 2020 | |
| Corium, LLC | $37.93 | 2023 | Adlarity |
| Ge Healthcare | $20.07 | 2024 | |
| Csl Behring | $20.00 | 2023 | Kcentra |
| Novo Nordisk INC | $19.79 | 2023 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Alberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.